Breast Cancer

Brian Czerniecki, MD, PhD, discusses the importance of utilizing a multidisciplinary effort to treat patients with breast cancer who develop brain or central nervous system metastases.

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Kamran A. Ahmed, MD, discusses key strategies to manage patients with breast cancer and brain metastases.

Christine Sam, MD, discusses strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Ian E. Krop, MD, PhD, discusses the pivotal data from the DESTINY-Breast01 trial, the need for longer-term follow-up with trastuzumab deruxtecan, and the proper management of interstitial lung disease.

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.